{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026160","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.982007+00:00","generated_at":"2026-06-12T17:43:58.952440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M","bullets":["Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).","Gross margin 61.6%, up from 54.8% in Q2 2022, driven by Coflex/CoFix contribution.","Net loss $2.2M ($0.02/share) vs $1.7M ($0.02) prior; adjusted EBITDA turned positive at $0.1M.","Raises FY 2023 revenue guidance to $75-77M from $73-75M, representing 29-33% annual growth.","CEO Sean Browne highlighted strength across channels and positive adjusted EBITDA ahead of expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026160","json":"https://secwatch.observer/filing/0001493152-23-026160.json","markdown":"https://secwatch.observer/filing/0001493152-23-026160.md","text":"https://secwatch.observer/filing/0001493152-23-026160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T17:43:58.952440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52fc0523bfa4701925e7e0832635f16f142ebc87","claim":"Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.","evidence_excerpt":"Second quarter 2023 revenue grew 32%, representing organic growth of 14% plus an 18% increase from products added in the acquisition of the Coflex and CoFix lines, to $20.2 million, compared to $15.3 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"-$2.2 million"},{"label":"EPS","value":"-$0.02"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"52fc0523bfa4701925e7e0832635f16f142ebc87","claim":"Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.","evidence_excerpt":"Second quarter 2023 net loss totaled $2.2 million, or $0.02 per share, compared to the second quarter 2022 net loss of $1.7 million, or $0.02 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"-$2.2 million"},{"label":"EPS","value":"-$0.02"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6fd2a746eb6ef6de0ce650b04d53de093f82ebd0","claim":"Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $75 million to $77 million. Guidance raised.","evidence_excerpt":"Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company's prior guidance of $73 million to $75 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$75 million to $77 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}